CJC-1295 no DAC is label shorthand for modified GRF 1-29: a 29-amino-acid growth-hormone-releasing hormone (GHRH) analog without the albumin-binding drug affinity complex. Without DAC, the molecule is short-acting—usually discussed in minutes rather than days—so it creates a brief stimulus rather than prolonged exposure. It is not simply a weaker dose of long-acting CJC-1295.
That distinction matters because the strongest human pharmacokinetic numbers belong to CJC-1295 with DAC. No published human pharmacokinetic study has established a precise half-life for the no-DAC molecule. A prescription or blend label should therefore identify the actual form instead of relying on "CJC-1295" alone.
What CJC-1295 no DAC means
DAC stands for drug affinity complex. The CJC backbone is a modified version of the active first 29 amino acids of GHRH. Four amino-acid substitutions make that backbone more resistant to enzymatic breakdown. The DAC form adds a reactive maleimide group that binds to circulating albumin, which acts as a long-lived carrier in the blood.
The no-DAC form keeps the modified 29-amino-acid backbone but leaves off that albumin-binding group. It is commonly called modified GRF 1-29, Mod GRF 1-29, or tetrasubstituted GRF 1-29. The often-quoted half-life of roughly 30 minutes is a useful shorthand, but it is not a value established by a published human trial of this exact molecule. The defensible conclusion is narrower: its exposure is measured in minutes rather than the multiple days documented for the DAC form.
The distinction is chemical, not just marketing. In its 2024 CJC-1295 briefing, the FDA treated CJC-1295 and CJC-1295 DAC as distinct active moieties and noted inconsistent naming across submitted materials.
What the human CJC-1295 studies actually tested
The landmark human data tested the long-acting DAC form. In two randomized, placebo-controlled dose studies, Teichman and colleagues reported an estimated half-life of 5.8 to 8.1 days. After a single injection, mean GH concentrations rose 2- to 10-fold for at least six days and mean IGF-1 rose 1.5- to 3-fold for 9 to 11 days (Journal of Clinical Endocrinology & Metabolism, 2006). Those are biomarker results in healthy adults, not evidence of better sleep, recovery, body composition, or another clinical outcome.
Ionescu and Frohman then sampled GH overnight in 12 healthy men before and one week after a single DAC-form dose. GH secretion increased while its pulsatile pattern remained intact (Journal of Clinical Endocrinology & Metabolism, 2006). That corrects an oversimplified comparison: DAC does not necessarily mean "no pulses." It means sustained drug exposure and a higher background stimulus, with GH pulses still detected in that small study.
None of those results supplies a precise human half-life, outcome claim, or established protocol for modified GRF 1-29.
CJC-1295 with DAC vs without DAC
| Label form | Albumin-binding DAC | Human duration evidence | Best description |
|---|---|---|---|
| Modified GRF 1-29 / CJC-1295 no DAC | Absent | No precise published human half-life | Brief GHRH-receptor stimulus; commonly described in minutes |
| CJC-1295 with DAC | Present | Half-life 5.8–8.1 days | Sustained exposure; GH pulsatility remained detectable in one small study |
Modified GRF 1-29 is also not the same molecule as sermorelin. Both are based on the active 1-29 segment of GHRH, but modified GRF contains four substitutions that sermorelin does not. The broader sermorelin versus CJC-1295 comparison owns the practical differences; the key point for reading a label is that "1-29" does not make the names interchangeable.
Why no-DAC blends pair it with ipamorelin
The pairing is based on two signaling routes. Modified GRF 1-29 acts at the GHRH receptor. Ipamorelin is a growth-hormone secretagogue that acts through the GHRP, or ghrelin, receptor. In an older human experiment, a GHRP combined with GHRH produced a larger acute GH response than either signal alone (Bowers et al., 1990). Separate preclinical work characterized ipamorelin as a selective GHRP-receptor agonist (Raun et al., 1998).
That is the physiological rationale for a blend, but it is not a clinical trial of CJC-1295 no DAC plus ipamorelin. It does not establish that the combination improves recovery, muscle, sleep, or body composition. The CJC-1295 and ipamorelin explainer covers the combination itself, while the CJC-1295/ipamorelin dosing page explains how a prescriber makes schedule decisions.
The trade-offs are about exposure, not a winner
Without DAC, exposure is brief and timing has more influence over when receptor stimulation occurs. That is why it fits the idea of a discrete signal and why it appears in blends with another short-acting secretagogue. The trade-off is that repeated administration may be considered and direct human evidence for the exact no-DAC molecule is especially thin.
With DAC, albumin binding produces multi-day exposure and the human studies document sustained GH and IGF-1 changes. The same persistence means effects cannot be adjusted as quickly after administration, and repeated doses showed cumulative IGF-1 elevation in the Teichman study.
Neither profile has been shown superior for patient-centered outcomes. The appropriate form depends on a prescriber's rationale, the patient's history, other medications, laboratory context, and tolerance—not on the idea that longer or more pulsatile automatically means better.
Approval status and what a prescription adds
CJC-1295 with DAC and modified GRF 1-29 are not FDA-approved for any indication. As of August 2026, the FDA's category 2 safety-risk page lists CJC-1295 and points to limited clinical data, potential immunogenicity, peptide-impurity and ingredient-characterization concerns, and reported increased heart rate and systemic vasodilatory reaction. That status should be stated neutrally rather than used as a marketing gate or a scare line.
Regulatory status is one input into care: a licensed provider may still prescribe a compounded formulation when clinically and legally appropriate, and that decision belongs to the patient and the doctor. A licensed provider reviews every request, and not everyone qualifies.
A prescription route also creates accountability that an anonymously sold vial does not. The record should identify the exact form, every ingredient in a blend, the pharmacy-set concentration and directions, and the clinician responsible for follow-up. The label term "no DAC" answers one chemistry question; it does not answer whether the product is suitable for a particular person.
The practical reading of “no DAC”
Read "no DAC" as a precise statement about structure: the albumin-binding extension is absent. It predicts a much shorter exposure than DAC-conjugated CJC-1295, but it does not prove greater safety, effectiveness, or physiological purity. The useful follow-up is a clinical explanation of why that form appears on the prescription, why ipamorelin is included if it is a blend, and what monitoring makes sense for that individual.